After the FDA approved both combination macitentan/tadalafil (Opsynvi) and the biologic therapy sotatercept (Winrevair) for ...

Research into prostacyclin analogs for the treatment of WHO Group 2 PH has been limited ... Phosphodiesterase type 5; PH: Pulmonary hypertension.

and reduced risk of clinical worsening events for people with WHO group 1 pulmonary hypertension. These "dramatic" benefits in ZENITH provide a mandate for use, noted study discussant Anjali ...

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with WHO Group 1 PAH FC 3 or 4 at high risk of mortality.

In 2021, a greater number of global pulmonary arterial hypertension cases occurred in females vs. males, and disease ...

[9] Consequently, a group of pulmonary hypertension specialists initiated a voluntary collaborative survey entitled Surveillance of North American Pulmonary Hypertension (SNAP). The goal of the ...

PHA launched a certificate program for healthcare professionals, providing specialized training for PH diagnosis, treatment, ...

Supporters will unite on May 5 to mark World Pulmonary Hypertension Day, with a focus this year on early diagnosis.

Pulmonary arterial hypertension (PAH ... The result: In the sotatercept group, the risk of deterioration resulting in a longer hospital stay, a lung transplant or even death was reduced by ...

in the placebo group; lung transplantation in 1 patient (1.2%) and 6 patients (7.0%), respectively; and hospitalization for worsening pulmonary arterial hypertension in 8 patients (9.3% ...